Market revenue in 2022 | USD 835.3 million |
Market revenue in 2030 | USD 1,469.2 million |
Growth rate | 7.3% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.96% in 2022. Horizon Databook has segmented the Italy hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Italy has around 22.8% population over the age of 65 years. It has the second-highest percentage of the oldest population in the world. Large geriatric population is highly susceptible to chronic diseases and thyroid disorders. Among females, postmenopausal issues are very commonly observed in this age group.
According to The Merck Serono Foundation, thyroid disease is a common condition in Italian inhabitants and ~10% of the population develops a thyroid disorder during their lifetime. Hypothyroidism affects ~5% of the general population.
Improving healthcare system, high investments in R&D, and favorable reimbursement policies are expected to fuel the market growth in the country. Servizio Sanitario Nazionale (SSN) provides universal coverage to Italian residents in Italy, with public health services mostly free for them.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Italy hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account